Alladapt Immunotherapeutics Receives FDA Fast Track Designation for ADP101 for the Treatment of Mono- and Multi-Food Allergies

<p>– Fast Track Designation accelerates ADP101’s development path for the treatment of mono- and multi-food allergy – – Phase 1/2 Harmony data for ADP101 recently presented at the 2023 American College of Asthma, Allergy and Immunology (ACAAI) Meeting demonstrate dose-dependent, clinically meaningful desensitization responses and a favorable safety profile in pediatric patients allergic to qualifying […]</p>
<p>The post <a href="https://forextv.com/top-news/alladapt-immunotherapeutics-receives-fda-fast-track-designation-for-adp101-for-the-treatment-of-mono-and-multi-food-allergies/">Alladapt Immunotherapeutics Receives FDA Fast Track Designation for ADP101 for the Treatment of Mono- and Multi-Food Allergies</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>